EGFR and non-small cell lung carcinoma: For the treatment of EGFR-mutated NSCLC, EGFR–tyrosine kinase inhibitors (EGFR–TKIs) that inhibit the EGFR-induced downstream signalling pathway by binding to the ATP-binding pocket of the EGFR–tyrosine kinase domain have been evaluated and are currently being clinically used2, 3, 4, 5, 6, 7, 8, 9.